Bioanalysis of siRNA and oligonucleotide therapeutics in biological fluids and tissues

Bioanalysis

Volumn 1, Issue 3, 2009, Pages 595-609

  Tremblay, Guy A ^a   Oldfield, Philip R ^a  

^a Immunochemistry Charles River Preclinical and Clinical Services   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; OLIGONUCLEOTIDE; SMALL INTERFERING RNA;

ANIMAL; BLOOD; CAPILLARY ELECTROPHORESIS; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; PHARMACOKINETICS; REVIEW; URINE;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ELECTROPHORESIS, CAPILLARY; HUMANS; IMMUNOASSAY; OLIGONUCLEOTIDES; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; RNA, SMALL INTERFERING; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 79952608699     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.09.66     Document Type: Review

References (105)

1. Manoharan M. RNA interference and chemically modifed small interfering RNAs. Curr. Opin. Chem. Biol. 8, 570-579 (2004).
2. Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell 136(4), 642-655 (2009).
3. Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference- based therapeutics. Nature 457(7228), 426-433 (2009).
4. Sahu NK, Shilakari G, Nayak A, Kohli DV. Antisense technology: a selective tool for gene expression regulation and gene targeting. Curr. Pharm. Biotechnol. 8(5), 291-304 (2007).
5. Kaur G, Roy I. Therapeutic applications of aptamers. Expert Opin. Investig. Drugs 17(1), 47-60 (2008).
6. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5(6), 471-484 (2006).
7. Dorn A, Kippenberger S. Clinical application of CpG-, non-CpG-, and antisense oligodeoxynucleotides as immunomodulators. Curr. Opin. Mol. Ther. 10(1), 10-20 (2008).
8. Petri A, Lindow M, Kauppinen S. MicroRNA silencing in primates: towards development of novel therapeutics. Cancer Res. 69(2), 393-395 (2009).
9. Sel S, Henke W, Dietrich A, Herz U, Renz H. Treatment of allergic asthma by targeting transcription factors using nucleic-acid based technologies. Curr. Pharm. Des. 12(25), 3293-3304 (2006).
10. van Ommen GJ, van Deutekom J, Aartsma-Rus A. The therapeutic potential of antisense-mediated exon skipping. Curr. Opin. Mol. Ther. 10(2), 140-149 (2008).
11. Bhindi R, Fahmy RG, Lowe HC et al. Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies. Am. J. Pathol. 171(4), 1079-1088 (2007).
12. Dua P, Kim S, Lee DK. Patents on SELEX and therapeutic aptamers. Recent Pat. DNA Gene Seq. 2(3), 172-186 (2008).
13. Halder J, Kamat AA, Landen CNJ et al. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin. Cancer Res. 12(16), 4916-4924 (2006).
14. Takeshita F, Minakuchi Y, Nagahara S et al. Effcient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc. Natl Acad. Sci. USA 102(34), 12177-12182 (2005).
15. Frank-Kamenetsky M, Grefhorst A, Anderson NN et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc. Natl Acad. Sci. USA 105(33), 11915-11920 (2008).
16. Sato Y, Murase K, Kato J et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specifc chaperone. Nat. Biotechnol. 26(4), 431-442 (2008).
17. Bitko V, Musiyenko A, Shulyayeva O, Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat. Med. 11(1), 50-55 (2005).
18. Song E, Lee SK, Wang J et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. 9(3), 347-351 (2003).
19. Niu, X-Y, Peng ZL, Duan WQ, Wang H, Wang P. Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo. Int. J. Gynecol. Cancer 16(2), 743-751 (2006).
20. Lee JF, Stovall GM, Ellington AD. Aptamer therapeutics advance. Curr. Opin. Chem. Biol. 10(3), 282-289 (2006).
21. Wolfrum C, Shi S, Jayaprakash KN et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol. 25, 1149-1157 (2007).
22. Amantana A, Moulton HM, Cate ML et al. Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate. Bioconjug. Chem. 18(4), 1325-1331 (2007).
23. Crooke ST. Antisense Drug Technology. Principles, Strategies, and Applications. CRC Press, Taylor & Francis Group, NY, USA (2008).
24. Brukner I, Tremblay GA. Cellular proteins prevent antisense phosphorothioate oligonucleotide (SdT18) to target sense RNA (rA18): development of a new in vitro assay. Biochemistry 39(37), 11463-11466 (2000).
25. Brown DA, Kang SH, Gryaznov SM et al. Effect of phosphorothioate modifcation of oligodeoxynucleotides on specifc protein binding. J. Biol. Chem. 269(43), 26801-26805 (1994).
26. Lee JH, Jucker F, Pardi A. Imino proton exchange rates imply an induced-ft binding mechanism for the VEGF165-targeting aptamer, Macugen. FEBS Lett. 582(13), 1835-1839 (2008).
27. Layzer JM, McCaffrey AP, Tanner AK, Huang Z, Kay MA, Sullenger BA. In vivo activity of nuclease-resistant siRNAs RNA. 10(5), 766-771 (2004).
28. Keefe AD, Cload ST SELEX with modifed nucleotides. Curr. Opin. Chem. Biol. 12(4), 448-456 (2008).
29. Allerson CR, Siouf N, Jarres R et al. Fully 2-modifed oligonucleotide duplexes with improved in vitro potency and stability compared with unmodifed small interfering RNA. J. Med. Chem. 48(4), 901-904 (2005).
30. Bauer S, Pigisch S, Hangel D, Kaufmann A, Hamm S. Recognition of nucleic acid and nucleic acid analogs by Toll-like receptors 7, 8 and 9. Immunobiology 213(3-4), 315-328 (2008).
31. Judge AD, Bola G, Lee AC, MacLachlan I. Design of noninfammatory synthetic siRNA mediating potent gene silencing in vivo. Mol. Ther. 13(3), 494-505 (2006).
32. Robbins M, Judge A, Ambegia E et al. Misinterpreting the therapeutic effects of siRNA caused by immune stimulation. Hum. Gene Ther. 19, 191-199 (2008).
33. Cook PD. Second generation antisense oligonucleotides: 2-modifcations. Annu. Rep. Med. Chem. 33, 313-325 (1998).
34. Prakash TP, Bhat B. 2-Modifed oligonucleotides for antisense therapeutics. Curr. Top. Med. Chem. 7(7), 641-649 (2007).
35. Geary RS, Yu RZ, Levin AA. Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr. Opin. Investig. Drugs 2(4), 562-573 (2001).
36. Chi KN, Zoubeidi A, Gleave ME. Custirsen (OGX-011). A second-generation antisense inhibitor of clusterin for the treatment of cancer. Expert Opin. Investig. Drugs 17(12), 1955-1962 (2008).
37. Muramaki M, So A, Hayashi N et al. Chemosensitization of gemcitabine-resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-apoptotic gene, clusterin. BJU Int. 103(3), 384-390 (2009).
38. Greenberger LM, Horak ID, Filpula D et al. A RNA antagonist of hypoxia-inducible factor-1a, EZN-2968, inhibits tumor cell growth. Mol. Cancer Ther. 7(11), 3598-3608 (2008).
39. You Y, Moreira BG, Behlke MA, Owczarzy R. Design of LNA probes that improve mismatch discrimination. Nucleic Acids Res. 34(8), E60 (2006).
40. Morcos PA, Li Y, Jiang S. Vivo-morpholinos: a non-peptide transporter delivers morpholinos into a wide array of mouse tissues. BioTechniques 45(6), 613-623 (2008).
41. Draper BW, Morcos PA, Kimmel CB. Inhibition of zebrafsh fgf8 pre-mRNA splicing with morpholino oligos: a quantifable method for gene knockdown. Genesis 30(3), 154-156 (2001).
42. Summerton J. Morpholino antisense oligomers: the case for an RNase-H independent structural type. Biochim. Biophys. Acta 1489(1), 141-158 (1999).
43. Wu B, Moulton HM, Iversen PL et al. Effective rescue of dystrophin improves cardiac function in dystrophin-defcient mice by a modifed morpholino oligomer. Proc. Natl Acad. Sci. USA 105(39), 14814-14819 (2008).
44. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 8(2), 129-138 (2009).
45. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4(2), 145-160 (2005).
46. Zimmermann TS, Lee A, Akinc A et al. RNAi-mediated gene silencing in non-human primates. Nature 441(7089), 111-114 (2006).
47. Thomas M, Lu J J, Ge Q, Zhang C, Chen J, Klibanov AM. Full deacylation of polyethylenimine dramatically boosts its gene delivery effciency and specifcity to mouse lung. Proc. Natl Acad. Sci. USA 102(16), 5679-5684 (2005).
48. Werth S, Urban-Klein B, Dai L et al. A low molecular weight fraction of polyethylenimine (PEI) displays increased transfection effciency of DNA and siRNA in fresh or lyophilized complexes. J. Control. Release 112(2), 257-270 (2006).
49. Heidel JD, Yu Z, Liu JY et al. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl Acad. Sci. USA 104(14), 5715-5721 (2007).
50. de Smet MD, Meenken CJ, van den Horn GJ. Fomivirsen-a phosphorothioate oligonucleotide for the treatment of CMV retinitis. Ocul. Immunol. Infamm. 7(3-4), 189-198 (1999).
51. Takeshima Y, Yagi M, Wada H et al. Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy. Pediatr. Res. 59(5), 690-694 (2006).
52. Kim ST, Lee KM, Park HJ, Jin SE, Ahn WS, Kim CK. Topical delivery of interleukin-13 antisense oligonucleotides with cationic elastic liposome for the treatment of atopic dermatitis. J. Gene Med. 11(1), 26-37 (2009).
53. Geary RS, Yu RZ, Watanabe T et al. Pharmacokinetics of a tumor necrosis factor-a phosphorothioate 2-O-(2-methoxyethyl) modifed antisense oligonucleotide: comparison across species. Drug Metab. Dispos. 31(11), 1419-1428 (2003).
54. Kim Y, Tewari M, Pajerowski JD et al. Polymersome delivery of siRNA and antisense oligonucleotides. J. Control. Release 134(2), 132-140 (2009).
55. Moschos SA, Spinks K, Williams AE, Lindsay MA. Targeting the lung using siRNA and antisense based oligonucleotides. Curr. Pharm. Des. 14(34), 3620-3627 (2008).
56. Zhang L, Tian X, Zhou F. Intranasal administration of CpG oligonucleotides induces mucosal and systemic Type 1 immune responses and adjuvant activity to porcine reproductive and respiratory syndrome killed virus vaccine in piglets in vivo. Int. Immunopharmacol. 7(13), 1732-1740 (2007).
57. Sommer W, Cui X, Erdmann B et al. The spread and uptake pattern of intracerebrally administered oligonucleotides in nerve and glial cell populations of the rat brain. Antisense Nucleic Acid Drug Dev. 8(2), 75-85 (1998).
58. Tillman LG, Geary RS, Hardee GE. Oral delivery of antisense oligonucleotides in man. J. Pharm. Sci. 97(1), 225-236 (2008).
59. Deverre JR, Boutet V, Boquet D, Ezan E, Grassi J, Grognet JM. A competitive enzyme hybridization assay for plasma determination of phosphodiester and phosphorothioate antisense oligonucleotides. Nucleic Acids Res. 25(18), 3584-3589 (1997).
60. Yu RZ, Baker B, Chappell A, Geary RS, Cheung E, Levin AA. Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma. Anal. Biochem. 304(1), 19-25 (2002).
61. Findlay J W, Dillard RF. Appropriate calibration curve ftting in ligand binding assays. AAPS J. 9(2), E260-E267 (2007).
62. Braasch DA, Corey DR. Locked nucleic acid (LNA). Fine-tuning the recognition of DNA and RNA. Chem. Biol. 8(1), 1-7 (2001).
63. Efer SM, Zhang L, Noll BO, Uhlmann E, Davis HL. Quantitation of oligodeoxynucleotides in human plasma with a novel hybridization assay offers greatly enhanced sensitivity over capillary electrophoresis. Oligonucleotides 15(2), 119-131 (2005).
64. Eder PS, Devine RJ, Dagle JM, Walder JA. Substrate specifcity and kinetics of degradation of antisense oligonucleotides by a 3́-exonuclease in plasma. Antisense Res. Dev. 1(2), 141-151 (1991).
65. Wójcik M, Cieslak M, Stec WJ, Goding JW, Koziołkiewicz M. Nucleotide pyrophosphatase/phosphodiesterase 1 is responsible for degradation of antisense phosphorothioate oligonucleotides. Oligonucleotides 17(1), 134-145 (2007).
66. Shenk TE, Rhodes C, Rigby PW, Berg P. Biochemical method for mapping mutational alterations in DNA with S1 nuclease: the location of deletions and temperature-sensitive mutations in simian virus 40. Proc. Natl Acad. Sci. USA 72(3), 989-993 (1975).
67. Till BJ, Burtner C, Comai L, Henikoff S. Mismatch cleavage by single-strand specifc nucleases. Nucleic Acids Res. 32(8), 2632-2641 (2004).
68. Kandimalla ER, Pandey RK, Agrawal S. Hybridization-based fuorescence assay allows quantitation of single-stranded oligodeoxynucleotides in low nanomolar range. Anal. Biochem. 328(1), 93-95 (2004).
69. Philips JA, Cragi SJ, Bayley D, Christian RA, Geary R, Nicklin PL. Pharmacokinetis, metabolism and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. Biochem. Pharmacol. 54(6), 657-668 (1997).
70. Boomer RM, Lewis SD, Healy JM, Kurz M, Wilson C, McCauley TG. Conjugation to polyethylene glycol polymer promotes aptamer biodistribution to healthy and infamed tissues. Oligonucleotides 15(3), 183-195 (2005).
71. Tavitian B. In vivo imaging with oligonucleotides for diagnosis and drug development. Gut 52(Suppl. 4), IV40-IV47 (2003).
72. Duatti A. In vivo imaging of oligonucleotides with nuclear tomography. Curr. Drug Targets 5(8), 753-760 (2004).
73. Bigelow JC, Chrin LR, Mathews LA, McCormack JJ. High-performance liquid chromatographic ana lysis of phosphorothioate analogues of oligodeoxynucleotides in biological fuids. J. Chromatogr. 533, 133-140 (1990).
74. Chen SH, Qian M, Brennan JM, Gallo JM. Determination of antisense phosphorothioate oligonucleotides and catabolites in biological fuids and tissue extracts using anion-exchange high-performance liquid chromatography and capillary gel electrophoresis. J. Chromatogr. B Biomed. Appl. 692(1), 43-51 (1997).
75. Arora V, Knapp DC, Reddy MT, Weller DD, Iversen PL. Bioavailability and effcacy of antisense morpholino oligomers targeted to c-myc and cytochrome P-450 3A2 following oral administration in rats. J. Pharm. Sci. 91(4), 1009-1018 (2002).
76. Banoub JH, Newton RP, Esmans E, Ewing DF, Mackenzie G. Recent developments in mass spectrometry for the characterization of nucleosides, nucleotides, oligonucleotides, and nucleic acids. Chem. Rev. 105(5), 1869-1915 (2005).
77. Dai G, Wei X, Liu Z, Liu S, Marcucci G, Chan KK. Characterization and quantifcation of Bcl-2 antisense G3139 and metabolites in plasma and urine by ion-pair reversed phase HPLC coupled with electrospray ion-trap mass spectrometry. J. Chromatogr. 825, 201-213 (2005).
78. Huber CG, Oberacher H. Analysis of nucleic acids by on-line liquid chromatography-mass spectrometry. Mass Spectrom. Rev. 20(5), 310-343 (2001).
79. Johnson JL, Guo W, Zang J et al. Quantifcation of Raf antisense oligonucleotide (rafAON) in biological matrices by LC-MS/MS to support pharmacokinetics of a liposome-entrapped rafAON formulation. Biomed. Chromatogr. 19(4), 272-278 (2005).
80. Apffel A, Chakel JA, Fischer S, Lichtenwalter K, Hancock WS. New procedure for the use of high-performance liquid chromatography electrospray ionization mass spectrometry for the ana lysis of nucleotides and oligonucleotides. J. Chromatogr. 777(1), 3-21 (1997).
81. Gaus HJ, Owens SR, Winniman M, Cooper S, Cummins LL. On-line HPLC electrospray mass spectrometry of phosphorothioate oligonucleotide metabolites. Anal. Chem. 69(3), 313-319 (1997).
82. Beck JL, Colgrave ML, Ralph SF, Sheil MM. Electrospray ionization mass spectrometry of oligonucleotide complexes with drugs, metals, and proteins. Mass Spectrom. Rev. 20(2), 61-87 (2001).
83. Richard C. Electrospray Ionization Mass Spectrometry: Fundamentals, Instrumentation, and Applications. Wiley, NY, USA (1997).
84. Zhang G, Lin J, Srinivasan K, Kavetskaia O, Duncan NJ. Strategies for bioana lysis of an oligonucleotide class macromolecule from rat plasma using liquid chromatography-tandem mass spectrometry. Anal. Chem. 79(9), 3416-3424 (2007).
85. Murphy AT, Brown-Augsburger P, Yu RZ, Geary RS, Thibodeaux S, Ackermann BL. Development of an ion-pair reverse-phase liquid chromatographic/tandem mass spectrometry method for the determination of an 18-mer phosphorothioate oligonucleotide in mouse liver tissue. Eur. J. Mass Spectrom. 11(2), 209-215 (2005).
86. Healy JM, Lewis SD, Kurz M et al. Pharmacokinetics and biodistribution of novel aptamer compositions. Pharm. Res. 21(12), 2234-2246 (2004).
87. ® Technology and Product Development. N V, USA, 20-23 May (2007).
88. Reyderman L, Stavchansky S. Quantitative determination of short single-stranded oligonucleotides from blood plasma using capillary electrophoresis with laser-induced fuorescence. Anal. Chem. 69(16), 3218-3222 (1997).
89. Freudemann T, von Brocke A, Bayer E. On-line coupling of capillary gel electrophoresis with electrospray mass spectrometry for oligonucleotide analysis. Anal. Chem. 73(11), 2587-2593 (2001).
90. Willems AV, Deforce DL, Van Peteghem CH, Van Bocxlaer JF. Analysis of nucleic acid constituents by on-line capillary electrophoresis-mass spectrometry. Electrophoresis 26(7-8), 1221-1253 (2005).
91. Taniguchi A, Kohsaka H, Carson DA. Competitive RT-PCR ELISA: a rapid, sensitive and non-radioactive method to quantitate cytokine mRNA. J. Immunol. Methods 169(1), 101-109 (1994).
92. Raymond CK, Roberts BS, Garrett-Engele P, Lim LP, Johnson JM. Simple, quantitative primer-extension PCR assay for direct monitoring of microRNAs and short-interfering RNAs. RNA 11(11), 1737-1744 (2005).
93. Allawi HT, Dahlberg JE, Olson S et al. Quantitation of microRNAs using a modifed invader assay. RNA 10(7), 1153-1161 (2004).
94. Duncan DD, Eshoo M, Esau C, Freier SM, Lollo BA. Absolute quantitation of microRNAs with a PCR-based assay. Anal. Biochem. 359(2), 268-270 (2006).
95. Chen C, Ridzon DA, Broomer AJ et al. Real-time quantifcation of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 33(20), E179 (2005).
96. Liu, W-L, Stevenson M, Seymour LW, Fisher KD. Quantifcation of siRNA using competitive qPCR. Nucleic Acids Res. 37(1), E4 (2008).
97. Viswanathan C T, Bansal S, Booth B et al. Workshop/conference report-quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. AAPS J. 9(1), 4 (2007).
98. DeSilva B, Smith W, Weiner R et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 20(11), 1885-1900 (2003).
99. Kelley M, DeSilva B. Key elements of bioanalytical method validation for macromolecules. AAPS J. 9(2), E156-E163 (2007).
100. Osaki M, Takeshita F, Ochiya T. MicroRNAs as biomarkers and therapeutic drugs in human cancer. Biomarkers 13(7-8), 658-670 (2008).
101. Aravin AA, Hannon GJ, Brennecke J. The Piwi-piRNA pathway provides an adaptive defense in the transposon arms race. Science 318(5851), 761-764 (2007).
102. Dunbar SA. Applications of Luminex xMAP technology for rapid, high-throughput multiplexed nucleic acid detection. Clin. Chim. Acta. 363(1-2), 71-82 (2006).
103. Zhang A, Pastor L, Nguyen Q et al. Small interfering RNA and gene expression ana lysis using a multiplex branched DNA assay without RNA purifcation. J. Biomol. Screen. 10(6), 549-556 (2005).
104. Judge AD, Robbins M, Tavakoli I et al. Confrming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J. Clin. Invest. 119(3), 661-673 (2009).
105. Qiu S, Adema CM, Lane T. A computational study of off-target effects of RNA interference. Nucleic Acids Res. 33(6), 1834-1847 (2005).